Research Evaluating Sports ConcUssion Events - Rapid Assessment of Concussion and Evidence for Return
RESCUE-RACER
1 other identifier
observational
103
1 country
1
Brief Summary
RESCUE-RACER is jointly sponsored by the University of Cambridge and Cambridge University Hospitals NHS Foundation Trust. The RESCUE-RACER programme evaluates motorsports competitors at baseline (CArBON) and post-injury (CARS). The CArBON study (Competitor Assessment at Baseline; Ocular, Neuroscientific) collects a battery of neuroscientific data in a baseline assessment. The CARS study (Concussion Assessment and Return to motorSport), repeats the CArBON battery throughout the recovery period in competitors who sustain a potentially concussive event during motorsport. The primary outcome of the RESCUE-RACER programme is to establish the natural history of concussive symptoms and signs in motorsport competitors using a comprehensive neuroscientific battery. The standard clinical assessment of concussive symptoms will be correlated with objective clinical scoring, in addition to neurocognitive and neuropsychological assessments. Advanced brain imaging with MRI will be used to further characterize head injuries in motorsport. Finally, salivary biomarkers will be collected to monitor the measurable biological effects of a potentially concussive event immediately following injury and through recuperation in the recovery period. The secondary outcome is investigation of a novel diagnostic tool for concussion, in the form of a 3D head-mounted display and eye tracking system capable of assessing ocular, vestibular and reaction time (OVRT) functions (the I-PAS device, now re-named Dx 100). The results of RESCUE-RACER will form an evidence base for medical decision-making track side after a potentially-concussive incident and will advise on clinic management of motorsports concussion, including the important 'return-to-race' decision.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Nov 2018
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 9, 2018
CompletedFirst Submitted
Initial submission to the registry
November 12, 2018
CompletedFirst Posted
Study publicly available on registry
February 18, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2022
CompletedDecember 12, 2023
December 1, 2023
2.1 years
November 12, 2018
December 8, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (5)
Change in SCAT5 decision scores
Change in performance on the Sports Concussion Assessment Tool 5 (SCAT5) from baseline to follow-up, as measured by sections of the assessment: 1. Symptoms - number (range 0-22) and severity (each rated as 0-6), summed to form a symptom severity score (range 0-132), with higher scores indicating worse symptoms \*For more information please see Step 2: Symptom Evaluation at link below\* 2. Orientation score 3. Immediate memory score 4. Concentration score 5. Neurological examination 6. Number of balance errors 7. Delayed recall score Which are combined to form a Decision (please see Step 6 at https://bjsm.bmj.com/content/bjsports/early/2017/04/26/bjsports-2017-097506SCAT5.full.pdf).
Baseline (CArBON assessments) to 1-3 weeks after concussion (CARS assessments)
Change in computerised neurocognitive assessment scores
Change in neurocognitive performance from baseline to follow-up, as measured by the Immediate Post-concussion Assessment and Cognitive Testing tool (ImPACT, please see https://impacttest.com/). This previously-validated assessment consists of the following sections: 1. Attention (including processing) 2. Memory (verbal and visual recognition; visual working) 3. Visual motor speed 4. Learning 5. Impulse control (response inhibition) 6. Delayed memory (repeat of verbal and visual tasks in 2) Which are combined to form Composite scores, whose calculation is defined in the ImPACT's Administration \& Interpretation Manual (available on request).
Baseline (CArBON assessment) to 1-3 weeks after concussion (CARS assessments)
Change in computerised neuropsychological assessment scores
Change in neuropsychological performance from baseline to follow-up, as measured by CANTAB Connect Research, the world's most validated, precise and reliable research software (please see http://www.cambridgecognition.com/products/cognitive-research/). This previously-validated assessment software consists of the following sections: 1. Attention (processing and psychomotor speed) 2. Memory (visual episodic) 3. Executive function and decision-making (working memory and strategy; planning). Each assessment produces a number of outputs, as detailed in the CANTAB Connect Research Overview Document (available on request).
Baseline (CArBON assessment) to 1-3 weeks after concussion (CARS assessments)
Change in the brain's microstructural architecture, or functional changes in the brain
Change in the brain's microstructural architecture, or functional changes in the brain, from baseline to follow-up as measured by: 1. High-resolution structural imaging - disruption of usual cerebral architecture (i.e. volume of sub/cortical structures) 2. Susceptibility-weighted imaging (SWI) - signal alteration 3. Diffusion-weighted imaging (DWI) - voxel intensity 4. Resting-state functional MRI (fMRI) - changes in blood oxygenation level 5. Proton spectroscopy
Baseline (CArBON assessment) to 1-3 weeks after concussion (CARS assessments)
Change in salivary biomarker levels
Change in the levels of salivary biomarkers from baseline to follow-up as potentially measured by markers of: 1. Neuronal injury - such as neurofilament light chain (NFL) 2. Glial injury - such as S100B (a calcium-binding peptide) 3. Epigenetic effects - as measured by micro RNA levels (miRNA) 4. Neurofibrillary degeneration - as measured by tau.
Baseline (CArBON assessments) to 1-3 weeks after concussion (CARS assessments)
Secondary Outcomes (1)
Altered performance in ocular, vestibular and reaction time (OVRT) assessment utilising the I-PAS/Dx100 device
Baseline (CArBON assessments) to 1-3 weeks after concussion (CARS assessments)
Study Arms (2)
CArBON (baseline)
The RESCUE-RACER programme is formed of two studies; baseline (CArBON) and one post-injury (CARS). At baseline the larger CArBON study involves completion of a thorough single baseline neuroscientific assessment of healthy motorsport competitors including clinical, neuropsychological, neurocognitive, biomarker and vestibulo-ocular assessments, in addition to MRI of the brain.
CARS (exposure to a potentially concussive event)
The RESCUE-RACER programme has a single post-injury study; after involvement in a potentially concussive event sustained during motorsport, CARS serially repeats the CArBON assessment battery in the immediate post-concussion recovery period. CARS participants will under-go post-exposure neuroscientific assessments immediately after injury and then at one, two and three weeks post-injury. If symptoms persist beyond this time, a further two assessments at monthly intervals will be offered.
Interventions
The SCAT5 is a standardized tool for evaluating sports-related concussions designed for use by physicians and licensed healthcare professionals in patients aged 13 years and above. It is a ten minute paper-based assessment which includes immediate and office/off-field assessments. SCAT5 incorporates the Maddocks' questions, Glasgow Coma Scale (GCS), cervical spine assessment and symptom evaluation, in addition to cognitive and neurological screening.
ImPACT (Immediate Post-Concussion Assessment and Cognitive Testing) is a neurocognitive assessment administered online or using desktop software in a controlled environment. ImPACT has two components: baseline testing and post-injury testing, both of which are used to determine if a patient can safely return to sporting activity post-concussion.
Originally developed at the University of Cambridge, the Cambridge Neuropsychological Test Automated Battery (CANTAB) platform includes highly sensitive, precise and objective measures of cognitive function, correlated to neural networks. These tests have demonstrated sensitivity to detecting changes in neuropsychological performance and include tests of working memory, learning and executive function; visual, verbal and episodic memory; attention, information processing and reaction time; social and emotion recognition, decision making and response control. The CANTAB touchscreen battery (www.camcog.com) will be utilised to perform neuropsychological assessments within RESCUE-RACER, whose study-specific protocol may include assessments of: Spatial Working Memory (working memory and strategy), Reaction Time (processing and psychomotor speed), Paired Associated Learning and the Multi-Tasking Test.
I-PAS™ (now re-named Dx 100) is a portable, head-mounted, neural functional assessment tool. With its integrated clinical eye tracking and digital display, the FDA has cleared (K171884) fourteen tests and an unmatched list of variables for clinical use for a variety of conditions. This utility of this device will be investigated for motorsport-related concussion.
Micro RNA's (miRNA's) are easily measured in saliva and have proven to have both diagnostic and prognostic use in sports-related concussion across the adolescent and adult populations, with levels persisting for some weeks after the concussive event. RESCUE-RACER will collect saliva samples for analysis of biomarkers of concussion, which may include miRNA and other markers of injury.
RESCUE-RACER participants will be invited to complete a functional MRI scan, whose 90-minute protocol may include: multi-parametric mapping (MPM), susceptibility weighted imaging (SWI), diffusion weighted imaging (DWI), proton spectroscopy and functional MRI (fMRI) with blood oxygenation-level dependent contrast (BOLD), completed at 7T (Tesla), or 3T if this is not possible.
Eligibility Criteria
Eligibility Criteria-CArBON; all competitors associated with the TOCA\* series or contracted by Aston Martin Racing (AMR) Eligibility Criteria-CARS; following exposure to a potentially concussive event sustained during motorsport activity: a) All competitors associated with the TOCA series or contracted by AMR b) Any competitive motorsports competitors who are referred to the Chief Investigator \*'TOCA' is a motorsports event package based in the UK (registered as a Patient Identification Centre, PIC). In 2019, TOCA consists of 6 semi-/professional racing series (3 adult-British Touring Car Championship (BTCC), Porsche Carrera Cup GB, Michelin Ginetta GT4 Supercup; 1 mixed age-Renault UK Clio Cup (17 years+); 2 adolescent (14-17 years)-Simpson Race Products Ginetta Junior Championships, British Formula 4 Championship; certified by Fédération Internationale de l'Automobile, FIA; powered by Ford).In 2020, Renault is replaced by the Mini Challenge series.
You may qualify if:
- a) Competitive motorsports participants
- Exposure to a potentially concussive event during motorsport activity OR a diagnosis of concussion during motorsport made by an experienced clinician \<3 weeks prior to referral.
- Mental capacity to consent to study participation
You may not qualify if:
- Age \<16 years
- Ongoing injuries so severe as to preclude study enrolment
- Recent (within the last 4 months) or current involvement in a research study involving administration of trial medication
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Cambridgelead
- Global Institute for Motorsport Safety (GIMSS) - Year 1collaborator
- Neurolign Technologies LLC (previously Neuro Kinetics Incorporated, NKI)collaborator
- Cambridge University Hospitals NHS (National Health Service) Foundation Trustcollaborator
- Federation Internationale de l'Automobile - Year 2 onwardscollaborator
Study Sites (1)
Mr Stephen Kelleher
Cambridge, Cambridgeshire, CB2 0QQ, United Kingdom
Related Publications (1)
Deakin ND, Suckling J, Hutchinson PJ. Research Evaluating Sports ConcUssion Events-Rapid Assessment of Concussion and Evidence for Return (RESCUE-RACER): a two-year longitudinal observational study of concussion in motorsport. BMJ Open Sport Exerc Med. 2021 Jan 13;7(1):e000879. doi: 10.1136/bmjsem-2020-000879. eCollection 2021.
PMID: 33500784DERIVED
Related Links
Biospecimen
Saliva will be collected from RESCUE-RACER participants during each study visit or assessment. All saliva samples will be centrifuged to render them acellular, therefore ensuring that they are no longer relevant material as defined by guidance from the United Kingdom (UK) Human Tissue Authority (see https://www.hta.gov.uk/policies/list-materialsconsidered-be-%E2% 80%98relevant-material%E2%80%99-under-human-tissue-act-2004).
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Peter J Hutchinson, MB BS FRCS (Surg Neurol)
University of Cambridge
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Study Coordinator
Study Record Dates
First Submitted
November 12, 2018
First Posted
February 18, 2019
Study Start
November 9, 2018
Primary Completion
December 31, 2020
Study Completion
December 31, 2022
Last Updated
December 12, 2023
Record last verified: 2023-12
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, ICF
- Time Frame
- CArBON data will be available following agreement of the report by all collaborators (estimated to be late 2020); CARS data will be handled in the same way (estimated middle of 2021).
- Access Criteria
- Data will only be made available to collaborators, subject to the programme's research agreement.
As per University of Cambridge and Cambridge University Hospitals, CUH, protocol, study data may be accessed by members of relevant clinical or research teams. A summary of anonymised aggregated data collected each year will be shared with the Funder in the form of an annual report. Linked and robustly anonymised OVRT data will be encrypted and electronically shared with collaborators at Neuro Kinetics Incorporated (now Neurolign) for the purpose of analysis, subject to a Data Transfer agreement approved by Cambridge University Hospitals (CUH, joint co-sponsor). Transfer of this study data will be in accordance with Health Research Authority (HRA) guidance 'Sharing of Anonymous Data Collected for Research Purposes'.